Retrospective evaluation of an observational cohort by the Central and Eastern Europe Network Group shows a high frequency of potential drug-drug interactions among HIV-positive patients receiving treatment for coronavirus disease 2019 (COVID-19)Observational Study Published on 2022-07-012023-07-07 Journal: HIV medicine [Category] COVID19(2023년), [키워드] combination antiretroviral therapy Coronavirus disease 2019 (COVID-19) drug-drug interaction HIV severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [DOI] 10.1111/hiv.13214 [Article Type] Observational Study
Neuropsychiatric manifestation of the drugs used in the treatment of SARS-2-CoV-2019 (COVID-19) infection and their management: An overview and practice implicationsSARS-2-CoV-2019(COVID-19) 감염 치료에 사용되는 약물의 신경정신병적 발현 및 그 관리: 개요 및 실행 의미Review Published on 2022-07-012022-09-11 Journal: Asian journal of psychiatry [Category] COVID19(2023년), SARS, 변종, 치료법, 치료제, [키워드] Adverse adverse effect Adverse reaction Affect Anti-COVID-19 medications complicate complications consequence COVID COVID-19 COVID-19 treatment dose drug drug-drug interaction drugs hcp Healthcare professional healthcare professionals help highlight implication Infection lAbel management manifestation medication medications myriad Neuropsychiatric off-label off-label use physical Primary infection Prognosis review risk factor Risk factors SARS-2-CoV-2019. Symptom Symptoms Topic Treatment treatment guideline treatment guidelines variant virulence virus [DOI] 10.1016/j.ajp.2022.103101 PMC 바로가기 [Article Type] Review
How far are we from predicting multi-drug interactions during treatment for COVID-19 infection?Article Published on 2022-07-012023-07-08 Journal: British Journal of Pharmacology [Category] COVID19(2023년), [키워드] Acute kidney injury biochemical simulations COVID-19 treatment drug-drug interaction intensive care unit [DOI] 10.1111/bph.15819
[Treatments for SARS-CoV-2 infection: A retrospective study of drug-drug interactions and safety][SARS-CoV-2 감염 치료: 약물간 상호작용과 안전성에 대한 후향적 연구]Review Published on 2022-07-012022-09-11 Journal: Annales pharmaceutiques françaises [Category] COVID19(2023년), SARS, 치료제, [키워드] Adverse Adverse drug reaction Adverse drug reactions adverse effect adverse effects adverse event adverse events analyzed association Azithromycin Causality caused conducted COVID-19 disease drug drug reaction drug-drug interaction Drug-drug interactions Effets secondaires et réactions indésirables d’origine médicamenteuse English epidemic wave French Hydroxychloroquine Incompatibilité entre médicaments Infection Lopinavir Lopinavir/ritonavir medical record Patient patients patients treated reported Retrospective study risk Ritonavir SARS-CoV-2 SARS-CoV-2 drug SARS-COV-2 infection [DOI] 10.1016/j.pharma.2021.11.001 PMC 바로가기 [Article Type] Review
Paxlovid (Nirmatelvir/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient with SARS-2-CoV infection: A Case ReportArticle Published on 2022-07-012022-11-15 Journal: Transplantation proceedings [Category] COVID19(2023년), SARS, 치료제, [키워드] Acute kidney injury acute respiratory syndrome addition adverse effects Affect antiviral medication approved Awareness Case report Combination Community Consulting coronavirus disease dose drug-drug interaction Efficiency Emergency use enzyme health systems Immunocompromised patient Immunosuppressive medication increase induce inhibit inhibitor interactions kidney transplant medication metabolites New P450 pandemic Patient Paxlovid physician Prevent receive receiving recipient reduction rejection report risk Ritonavir robust SARS-CoV-2 serum creatinine Side effects Symptoms tacrolimus tested Transplant treat treated Treatment [DOI] 10.1016/j.transproceed.2022.04.015 PMC 바로가기
Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19낭포성 섬유증 환자를 위한 생리학적 기반 약동학 주도 지침Article Published on 2022-06-012022-09-11 Journal: Clinical Pharmacology and Therapeutics [Category] 변종, [키워드] Administered approach AUC CFTR Combination coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 infection Cystic cystic fibrosis cytochrome P450 Day decrease dose drug interaction drug-drug interaction elexacaftor eliminated evaluated fibrosis independent information inhibited inhibiting inhibitor inhibitory effect ivacaftor metabolism modeling modulating Nirmatrelvir P450 parameter pharmacokinetic pharmacokinetics physiological predict predicted reduced regimen risk Ritonavir Simulation Taking tezacaftor therapeutic Therapies transmembrane Treatment was performed [DOI] 10.1002/cpt.2585 PMC 바로가기 [Article Type] Article
Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT)Research article Published on 2022-04-012022-10-05 Journal: Thérapie [Category] COVID19(2023년), SARS, 치료제, [키워드] acute respiratory syndrome Adverse drug reaction Antiviral association clinician Combination complex Contact coronavirus Course cysteine protease draft drug drug monitoring drug-drug interaction Efficacy enhancer enzyme Final French guideline help high risk management Modification modifications MPro National Nirmatrelvir objective Participants patients treated Paxlovid Pfizer Pharmacodynamics pharmacokinetic pharmacokinetics Pharmacology Pragmatic Prevent primary care protease recommendation recommendations Result Ritonavir SARS-CoV-2 secure Society therapeutic therapeutic strategy Therapeutics Treatment [DOI] 10.1016/j.therap.2022.03.005 [Article Type] Research article
Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: A evidence-based review from six databases심장 보호 약물과 COVID-19 치료에 사용되는 약물 간의 약물 상호 작용 위험: 6개 데이터베이스의 증거 기반 검토Review Published on 2022-03-012022-09-11 Journal: Diabetes & metabolic syndrome [Category] SARS, 변종, 신약개발, 치료법, 치료제, [키워드] acting antihypertensive drugs approved Atazanavir Azithromycin cardiovascular system caution Chloroquine close monitoring comorbid condition comorbid conditions Comorbidity concomitant use COVID COVID- 19 treatment COVID-19 COVID-19 infection COVID-19 treatment database Dexamethasone diabetes dosage drug drug interaction drug-drug interaction drugs Effect Effects ENhance Evidence Factor FDA glycemic control group hypertension Hypotension Improving Infection information Interaction interaction effect life Lopinavir Lopinavir/ritonavir Medicine Medscape molnupiravir monoclonal antibodies monoclonal antibody Nirmatrelvir Patient Paxlovid polypharmacy Potential Quality of life Remdesivir resulting review risk Ritonavir therapeutic efficacy therapy treating COVID-19 Treatment worsening [DOI] 10.1016/j.dsx.2022.102451 PMC 바로가기 [Article Type] Review
Dexamethasone is a dose-dependent perpetrator of drug-drug interactions: implications for use in people living with HIVDexamethasone은 약물-약물 상호작용의 용량 의존적 가해자입니다.Article Published on 2022-02-232022-09-11 Journal: Journal of Antimicrobial Chemotherapy [Category] COVID19(2023년), SARS, 치료제, [키워드] antiretroviral ARV assessment complex Course COVID-19 patient CYP3A4 cytochrome P450 daily dose Dexamethasone dosage dose-dependent drug-drug interaction drugs evaluated implication in vitro in vivo inducer inhibitor inhibitors Interaction management P450 recommendation substrate substrates Treatment victim with HIV [DOI] 10.1093/jac/dkab412 PMC 바로가기 [Article Type] Article
Induction of CD73 prevents death after emergency open aortic surgery for a ruptured abdominal aortic aneurysm: a randomized, double-blind, placebo-controlled studyArticle Published on 2022-02-032022-10-04 Journal: Scientific Reports [Category] 바이오마커, [키워드] 95% CI adverse event all-cause mortality Analysis Aneurysm anticipated aortic aneurysm ARDS baseline blocked with CD73 cluster of differentiation concerning concomitant use congestive heart failure D30 death demonstrated diagnosed double-blind drug-drug interaction Efficacy and safety exclusion criteria glucocorticoid Hemorrhagic IFN IMPROVE induction initial interim analysis intestinal intravenous Ischemia Liver cirrhosis Major malignant disease matching placebo mechanism Neutralizing antibodies neutralizing antibody outcome outcome measure parallel group Patient Placebo placebo-controlled study postoperative Prevent Pyrexia Randomized randomized patient Registered renal replacement therapy reported serum Shock statistically significant difference suggested surgery survival survived treated Treatment treatment group Trial up-regulating [DOI] 10.1038/s41598-022-05771-1 PMC 바로가기 [Article Type] Article